<DOC>
	<DOCNO>NCT00287482</DOCNO>
	<brief_summary>This pilot feasibility study perform woman complete front-line treatment breast ovarian cancer . It do evaluate whether herbal combination know Essiac ( ESIAK ) improve overall quality life woman transition active treatment follow-up , also know quality life transition . This information use design large randomized trial .</brief_summary>
	<brief_title>Essiac ( ESIAK ) Versus Placebo Improve Quality Life Transition Women With Breast Ovarian Cancer .</brief_title>
	<detailed_description>Complementary Alternative medical ( CAM ) practice “ healthcare practice outside realm conventional medicine , yet validate use scientific method ” . It encompass wide variety behavioral ( meditation , spiritual practice ) clinical ( herbal , acupuncture , massage ) technique . Patients chronic disease include cancer tend interested treatment research involve CAM ability improve quality life need . Women transition active treatment breast ovarian cancer surveillance ( QOL-T ) experience physical psychological distress , relate treatment ( fatigue , alopecia , menopausal symptom ) , diagnosis . Intervention critical time transition active therapy follow-up may help patient adjust life cancer treatment . Essiac document popular form herbal treatment patient cancer . Given lack report side effect , interested pursue formal evaluation Essiac capsule formulation ( ESIAK ) woman survive breast ovarian cancer evaluate role improve overall quality life follow chemotherapy often accompany end adjuvant therapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Inclusion Criteria histologically document diagnosis infiltrate carcinoma breast epithelial ovarian cancer . Given similar clinical course patient fallopian tube primary peritoneal carcinoma patient also include study . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Patients must either postmenopausal surgically sterilize willing use acceptable method birth control ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Women childbearing potential must negative pregnancy test . If patient become pregnant course study , allow continue study . age ≥ 18 yearold Karnofsky performance status &gt; 70 % Ability understand willingness sign inform consent Ability perform comply followup study No history drug alcohol abuse No antecedent history depression prior diagnosis malignancy Must ≥ 4 week completion chemotherapy radiation therapy . Adequate hematopoietic function define : ANC ≥ 1500/mm3 ; Platelets ≥ 100,000/mm3 ; Hemoglobin ≥ 8 g/dL . Adequate renal hepatic function define : Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; SGOT ≤ 2.5 time ULN ; Alkaline phosphatase ≤ 2.5 time ULN ; Creatinine ≤ 2 time ULN . For patient epithelial ovarian , fallopian tube , primary peritoneal cancer ( EOC/FT/PPC ) : patient must complete frontline treatment within 3 month study entry complete remission ; Patients treat neoadjuvant platinumbased chemotherapy prior definitive surgery eligible ; If serum CA125 elevate diagnosis , must also normalized end treatment . For patient breast cancer : patient must complete adjuvant treatment chemotherapy radiation therapy ( recommend ) within three month study entry deem complete remission ; Treatment must include adjuvant chemotherapy radiation recommend ; Patients receive neoadjuvant therapy eligible follow completion adjuvant chemotherapy indicate . Patients receive hormonal therapy follow chemotherapy eligible participate . However , patient place Tamoxifen hormonal agent lieu chemotherapy eligible . Exclusion Criteria history active secondary cancer within last 5 year , except superficial basal cell skin cancer residual chemotherapyinduced CTCv3.0 Grade 2 great nonhematologic toxicity unable give inform consent unable adhere protocol Serious medical psychiatric illness likely interfere participation clinical study concurrent uncontrolled illness ongoing active infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Treatment side effect</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Transition</keyword>
	<keyword>Survivorship</keyword>
</DOC>